Full Text Journal Articles by
Author Vanita R Aroda

Advertisement

Find full text journal articles






Development and validation of a predictive model algorithm to identify anaphylaxis in adults with type 2 diabetes in U.S. administrative claims data.

Daniel C Beachler, Devon H Taylor, Mary S Anthony, Ruihua Yin, Ling Li, Catherine W Saltus, Lin Li, Alka Shaunik, Kathleen E Walsh, Kenneth J Rothman, Catherine B Johannes, Vanita R Aroda, Warner Carr, Pinkus Goldberg, Andrew Accardi, John Shane O'Shura, Kristen Sharma, Juhaeri Juhaeri, Stephan Lanes, Chuntao Wu,

<h4>Purpose</h4>To use medical record adjudication and predictive modeling methods to develop and validate an algorithm to identify anaphylaxis among adults with type 2 diabetes (T2D) in administrative claims.<h4>Methods</h4>A conventional screening algorithm that prioritized sensitivity to identify potential anaphylaxis cases was developed and consisted of diagnosis codes for anaphylaxis or relevant ... Read more >>

Pharmacoepidemiol Drug Saf (Pharmacoepidemiology and drug safety)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.

Geremia B Bolli, Alice Cheng, Bernard Charbonnel, Vanita R Aroda, Jukka Westerbacka, Zsolt Bosnyak, Emmanuelle Boëlle-Le Corfec, Julio Rosenstock,

<h4>Aim</h4>To evaluate the efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus insulin degludec 100 U/mL (IDeg-100) in predefined (</≥65 years) and post hoc (</≥70 years) age groups of people with type 2 diabetes (T2D) in the BRIGHT trial.<h4>Materials and methods</h4>BRIGHT was the first head-to-head randomized trial comparing Gla-300 and Deg-100 in insulin-naïve ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study.

Lawrence Blonde, Julio Rosenstock, Juan Frias, Andreas L Birkenfeld, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Stefano Del Prato, Vanita R Aroda,

<h4>Objective</h4>In the LixiLan-G trial, switching to iGlarLixi, a once-daily titratable fixed-ratio combination of insulin glargine 100 units/mL and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide, improved glucose control in type 2 diabetes uncontrolled with GLP-1 RAs over 26 weeks versus continuing prior GLP-1 RA. A prespecified, 26-week, single-arm ... Read more >>

Diabetes Care (Diabetes care)
[2021, 44(3):774-780]

Cited: 0 times

View full text PDF listing >>



Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.

Julio Rosenstock, Lawrence Blonde, Vanita R Aroda, Juan Frias, Elisabeth Souhami, Chen Ji, Elisabeth Niemoeller, Stefano Del Prato,

<h4>Aim</h4>In people with type 2 diabetes (T2D) requiring intensification beyond glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and oral antihyperglycaemic drugs (OADs), switching to iGlarLixi was shown to be efficacious and well-tolerated in the LixiLan-G trial. This exploratory analysis of LixiLan-G assessed the efficacy and safety of switching to iGlarLixi versus ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Circulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program.

Vanita R Aroda, Costas A Christophi, Sharon L Edelstein, Leigh Perreault, Catherine Kim, Sherita H Golden, Edward Horton, Kieren J Mather, ,

<h4>Introduction</h4>Sex hormone binding globulin (SHBG) levels are reported to be inversely associated with diabetes risk. It is unknown whether diabetes prevention interventions increase SHBG and whether resultant changes in SHBG affect diabetes risk. The purpose of this analysis was to determine whether intensive lifestyle intervention (ILS) or metformin changed circulating ... Read more >>

BMJ Open Diabetes Res Care (BMJ open diabetes research & care)
[2020, 8(2):]

Cited: 0 times

View full text PDF listing >>



EMPA-REG OUTCOME and beyond: the long game of cardiovascular risk reduction.

Vanita R Aroda, Marc S Sabatine,

Lancet Diabetes Endocrinol (The lancet. Diabetes & endocrinology)
[2020, 8(12):932-933]

Cited: 0 times

View full text PDF listing >>



Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.

Christopher K Rayner, Tongzhi Wu, Vanita R Aroda, Craig Whittington, Steve Kanters, Patricia Guyot, Alka Shaunik, Michael Horowitz,

<h4>Aims</h4>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the recommended first injectable therapy in type 2 diabetes. However, long-term persistence is suboptimal and partly attributable to gastrointestinal tolerability, particularly during initiation/escalation. Gradual titration of fixed-ratio combination GLP-1 RA/insulin therapies may improve GLP-1 RA gastrointestinal tolerability. We compared gastrointestinal adverse event (AE) ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2021, 23(1):136-146]

Cited: 1 time

View full text PDF listing >>



Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses.

Richard E Pratley, Vanita R Aroda, Andrei-Mircea Catarig, Ildiko Lingvay, Jörg Lüdemann, Emre Yildirim, Adie Viljoen,

<h4>Objective</h4>In SUSTAIN 7, once-weekly semaglutide demonstrated superior glycated haemoglobin (HbA<sub>1c</sub>) and body weight (BW) reductions versus once-weekly dulaglutide in subjects with type 2 diabetes (T2D). This <i>post hoc</i> analysis investigated the impact of clinically relevant subject characteristics on treatment effects of semaglutide versus dulaglutide.<h4>Design</h4>Analyses by baseline age (<65, ≥65 years), ... Read more >>

BMJ Open (BMJ open)
[2020, 10(11):e037883]

Cited: 0 times

View full text PDF listing >>



Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.

Michael C Honigberg, Lee-Shing Chang, Darren K McGuire, Jorge Plutzky, Vanita R Aroda, Muthiah Vaduganathan,

<h4>Importance</h4>Recent randomized clinical trials have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce cardiovascular events in at-risk individuals with type 2 diabetes. Despite these findings, GLP-1RAs are underused in eligible patients, particularly by cardiologists.<h4>Observations</h4>To date, randomized clinical trials of albiglutide, dulaglutide, liraglutide, and injectable semaglutide have reported favorable cardiovascular outcomes. ... Read more >>

JAMA Cardiol (JAMA cardiology)
[2020, 5(10):1182-1190]

Cited: 1 time

View full text PDF listing >>



Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.

Eugene E Wright, Vanita R Aroda,

Injectable therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and insulin are high-efficacy options for people with type 2 diabetes (T2D) who require treatment intensification. In addition to high glycemic efficacy, GLP-1RAs offer weight loss benefits, and some agents have been shown to reduce cardiovascular risk. This article summarizes data ... Read more >>

Postgrad Med (Postgraduate medicine)
[2020, 132(sup2):26-36]

Cited: 0 times

View full text PDF listing >>



Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists: a systematic literature review and indirect treatment comparison.

Philip D Home, Vanita R Aroda, Lawrence Blonde, Patricia Guyot, Alka Shaunik, Mir Sohail Fazeli, Hardik Goswami, Sanjay Kalra, Mir-Masoud Pourrahmat,

<h4>Aims</h4>To estimate the relative treatment effect between the fixed-ratio combinations iGlarLixi and IDegLira (glucagon-like peptide 1 receptor agonist with basal insulin) in people with type 2 diabetes inadequately controlled on a glucagon-like peptide 1 receptor agonist.<h4>Materials and methods</h4>A systematic literature review of randomized controlled trials followed by an indirect treatment ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, 22(11):2170-2178]

Cited: 0 times

View full text PDF listing >>



Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials.

Jack A Sargeant, Emer M Brady, Francesco Zaccardi, Frances Tippins, David R Webb, Vanita R Aroda, Edward W Gregg, Kamlesh Khunti, Melanie J Davies,

<h4>Aims/hypothesis</h4>Early-onset adult type 2 diabetes (diagnosed between ages 18 and 39 years) is increasingly prevalent and associated with poor long-term outcomes. We hypothesised that individuals with early-onset adult type 2 diabetes were underrepresented in the prominent research trials that underpin type 2 diabetes management guidelines.<h4>Methods</h4>We reviewed the mean age of the ... Read more >>

Diabetologia (Diabetologia)
[2020, 63(8):1516-1520]

Cited: 0 times

View full text PDF listing >>



Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.

Stefano Del Prato, Juan Pablo Frias, Lawrence Blonde, Vanita R Aroda, Niam Shehadeh, Aramesh Saremi, Terry Dex, Elisabeth Niemoeller, Elisabeth Souhami, Minzhi Liu, Julio Rosenstock,

<h4>Aim</h4>To evaluate the efficacy of iGlarLixi by C-peptide levels and duration of diabetes in an exploratory analysis of the LixiLan-G study.<h4>Methods</h4>LixiLan-G was a 26-week, randomized, open-label study in adults with type diabetes (T2D) inadequately controlled while on a glucagon-like peptide-1 receptor agonist (GLP-1 RA), with metformin, with or without pioglitazone ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, 22(9):1567-1576]

Cited: 1 time

View full text PDF listing >>



iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study.

Nicola Morea, Ravi Retnakaran, Josep Vidal, Vanita R Aroda, Minzhi Liu, Aramesh Saremi, Francesco Giorgino,

Globally, nearly half of patients with type 2 diabetes (T2D) do not successfully achieve target HbA1c with basal insulin, despite meeting fasting plasma glucose (FPG) targets. In this post hoc analysis of the LixiLan-L study, we determined whether iGlarLixi, a fixed-ratio combination of insulin glargine Gla-100 (iGlar) and the glucagon-like ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, 22(9):1683-1689]

Cited: 3 times

View full text PDF listing >>



Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight.

William I Sivitz, Lawrence S Phillips, Deborah J Wexler, Stephen P Fortmann, Anne W Camp, Margaret Tiktin, Magalys Perez, Jacqueline Craig, Priscilla A Hollander, Andrea Cherrington, Vanita R Aroda, Meng Hee Tan, Jonathan Krakoff, Neda Rasouli, Nicole M Butera, Naji Younes, ,

<h4>Objective</h4>We evaluated the effect of optimizing metformin dosing on glycemia and body weight in type 2 diabetes.<h4>Research design and methods</h4>This was a prespecified analysis of 6,823 participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) taking metformin as the sole glucose-lowering drug who completed a 4- ... Read more >>

Diabetes Care (Diabetes care)
[2020, 43(5):940-947]

Cited: 1 time

View full text PDF listing >>



Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L.

Lawrence Blonde, Lori Berard, Aramesh Saremi, Yao Huang, Vanita R Aroda, Denis Raccah,

<h4>Introduction</h4>With longer duration and progression of type 2 diabetes (T2D), β-cell function deteriorates and insulin therapy often becomes necessary. Glucagon-like peptide-1 receptor agonists such as lixisenatide that do not rely only on β-cell function and glucagon suppression primarily, but also lower glucose by other (insulin-independent) mechanisms such as delayed gastric ... Read more >>

Diabetes Ther (Diabetes therapy : research, treatment and education of diabetes and related disorders)
[2020, 11(4):1007-1015]

Cited: 1 time

View full text PDF listing >>



Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes.

Daniel S Hsia, Neda Rasouli, Anastassios G Pittas, Christine W Lary, Anne Peters, Michael R Lewis, Sangeeta R Kashyap, Karen C Johnson, Erin S LeBlanc, Lawrence S Phillips, James M Hempe, Cyrus V Desouza, ,

<h4>Objective</h4>Fasting plasma glucose (FPG), 2-hour plasma glucose (2hPG) from a 75-g oral glucose tolerance test (OGTT) and glycated hemoglobin (HbA1c) can lead to different results when diagnosing prediabetes and diabetes. The Hemoglobin Glycation Index (HGI) quantifies the interindividual variation in glycation resulting in discrepancies between FPG and HbA1c. We used ... Read more >>

J Clin Endocrinol Metab (The Journal of clinical endocrinology and metabolism)
[2020, 105(3):]

Cited: 2 times

View full text PDF listing >>



A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.

Giorgio Sesti, Lars Bardtrum, Selcuk Dagdelen, Natalie Halladin, Martin Haluzík, Petra Őrsy, Martin Rodríguez, Vanita R Aroda,

This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants (N = 1012) with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs) were randomized 1:1 to ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, 22(5):873-878]

Cited: 1 time

View full text PDF listing >>



Reproducibility of a prediabetes classification in a contemporary population.

Chhavi Chadha, Anastassios G Pittas, Christine W Lary, William C Knowler, Ranee Chatterjee, Lawrence S Phillips, Vanita R Aroda, Michael R Lewis, Richard Pratley, Myrlene A Staten, Jason Nelson, Neda Rasouli, Irwin Brodsky, ,

Aims:To assess whether meeting both fasting plasma glucose (FPG) and HbA1c criteria for prediabetes in people at high risk indicates with near certainty the presence of dysglycemia on repeat testing. Methods:Observational study using data from Vitamin D and Type 2 Diabetes (D2d) study. HbA1c, FPG were measured at screening visit ... Read more >>

Metabol Open (Metabolism open)
[2020, 6:100031]

Cited: 0 times

View full text PDF listing >>



Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.

Lee-Shing Chang, Muthiah Vaduganathan, Jorge Plutzky, Vanita R Aroda,

PURPOSE OF REVIEW:Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in individuals with type 2 diabetes (T2D). Recent cardiovascular outcome trials (CVOTs) have established sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1 RA) as powerful medications that can lower glucose as well as reduce the ... Read more >>

Curr Diab Rep (Current diabetes reports)
[2019, 19(12):157]

Cited: 1 time

View full text PDF listing >>



Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials.

Vanita R Aroda, Matthew S Capehorn, Louis Chaykin, Juan P Frias, Nanna L Lausvig, Stanislava Macura, Jörg Lüdemann, Sten Madsbad, Julio Rosenstock, Omur Tabak, Sayeh Tadayon, Stephen C Bain,

<h4>Aim</h4>To evaluate the impact of relevant patient-level characteristics on the efficacy and safety of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes.<h4>Materials and methods</h4>Exploratory post hoc analyses of pooled SUSTAIN 1-5 (phase 3a) randomized, controlled trials examined the change from baseline in HbA1c and body weight (BW), and the ... Read more >>

Diabetes Obes Metab (Diabetes, obesity & metabolism)
[2020, 22(3):303-314]

Cited: 1 time

View full text PDF listing >>



Erratum. Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. Diabetes Care 2018;41:1590-1599.

Erin S LeBlanc, Richard E Pratley, Bess Dawson-Hughes, Myrlene A Staten, Patricia R Sheehan, Michael R Lewis, Anne Peters, Sun H Kim, Ranee Chatterjee, Vanita R Aroda, Chhavi Chadha, Lisa M Neff, Irwin G Brodsky, Clifford Rosen, Cyrus V Desouza, John P Foreyt, Daniel S Hsia, Karen C Johnson, Philip Raskin, Sangeeta R Kashyap, Patrick O'Neil, Lawrence S Phillips, Neda Rasouli, Emilia P Liao, David C Robbins, Anastassios G Pittas, ,

Diabetes Care (Diabetes care)
[2019, 42(12):2347]

Cited: 0 times

View full text PDF listing >>



Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.

Bernard Zinman, Vanita R Aroda, John B Buse, Bertrand Cariou, Stewart B Harris, Søren Tetens Hoff, Karen Boje Pedersen, Mads Jeppe Tarp-Johansen, Eiichi Araki, ,

<h4>Objective</h4>To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin.<h4>Research design and methods</h4>Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg (<i>N</i> = 184), 7 mg (<i>N</i> = 182), or 14 mg (<i>N</i> ... Read more >>

Diabetes Care (Diabetes care)
[2019, 42(12):2262-2271]

Cited: 15 times

View full text PDF listing >>



Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.

Lawrence Blonde, Julio Rosenstock, Stefano Del Prato, Robert Henry, Naim Shehadeh, Juan Frias, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Vanita R Aroda,

<h4>Objective</h4>Fixed-ratio combinations of basal insulin plus glucagon-like peptide 1 receptor agonist (GLP-1 RA) allow concomitant administration of two proven complementary injectable therapies for type 2 diabetes. This study investigated switching to a titratable fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) in patients with type 2 diabetes receiving daily or ... Read more >>

Diabetes Care (Diabetes care)
[2019, 42(11):2108-2116]

Cited: 5 times

View full text PDF listing >>



Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.

Lawrence Blonde, Timothy S Bailey, Jason Chao, Terry A Dex, Juan Pablo Frias, Luigi F Meneghini, Michelle Roberts, Vanita R Aroda,

<h4>Introduction</h4>iGlarLixi is a titratable, fixed-ratio combination of insulin glargine (iGlar, 100 units/ml) and the glucagon-like peptide-1 receptor agonist lixisenatide for the treatment of patients with type 2 diabetes. This post hoc analysis of the phase 3 LixiLan-L trial (NCT02058160) investigated baseline characteristics, glycemic control, and safety outcomes in participants who ... Read more >>

Adv Ther (Advances in therapy)
[2019, 36(9):2310-2326]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.1037 s